HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB: ARDM) (the “Company”) today announced it has initiated a multicenter Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.
